The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid intensifying scrutiny of genetic testing firms, GeneDx faces a securities class action lawsuit following a 49% drop in its stock price in May 2026. The legal action is directly tied to the company's write-off of 94% of assets connected to its acquisition of Fabric Genomics. According to reports, the massive valuation collapse followed the release of disappointing Q1 2026 earnings results.
The legal challenge, led by Hagens Berman, alleges that investors were misled regarding the long-term value of the Fabric Genomics deal originally struck in 2022. In comparison to genomic peers, companies like Invitae and Myriad Genetics have maintained more stable valuations, highlighting the specific impact of GeneDx's accounting adjustments. Per market data, the 94% impairment charge represents one of the most significant asset devaluations in the biotech sector this year.
Sign in to access this content
Sign InWGS shares stood at $60.99 (close June 11, 2026), having traded between a low of $52.51 and a high of $61.25 during the session. Investors should monitor further legal filings for potential impacts on corporate liquidity, as the upcoming economic calendar remains light on healthcare catalysts, with broader market attention shifting toward global inflation data.